The example outlined demonstrates an early success of the Resonant platform prior to full platform scale-up, where dozens of equal or greater caliber candidates have been generated. Although only a couple of hundred clones were generated in this early run, among these was the high-value candidate RT-00001. This antibody targets a protein specifically expressed in the tumor microenvironment, highly efficacious as a single agent therapeutic, and would not have been discovered by industry standard screening methods.
RT-00001 is therapeutically active against physiological tumor cells, but not in standard 2D cultures. The target for RT-00001 has been overlooked by standard industry approaches before.
Tumor tissue biopsy specimens from pancreatic, melanoma, breast, colon, and brain tumors demonstrate widespread RT-00001 target overexpression in these cancer types. Normal tissues from these same sites show little to no RT-00001 staining.
RT-00001 significantly inhibits MDA-MB-231 metastasis and growth in an in vivo mouse model. Luciferase expressing MDA-MB-231 cells were injected into the left ventricle of nude mice and treated with control ab or RT-00001 twice weekly for 4 weeks.